Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change

Executive Summary

“We’re not looking for a lot of turnover. I think we have a team that works very well together,” HHS Deputy Secretary Eric Hargan said.

You may also be interested in...



Triangulation Or The Bermuda Triangle: Can Trump Work With House Dems On Drug Prices?

President Trump is highlighting drug pricing as an area where he may be able to work with the new Democratic majority in the House. The political wisdom of building common ground on the topic is hard to ignore – but the tempestuous personality of the President is still the overriding factor. Instead, focus on whether HHS can win some breathing room to keep going with administrative changes.

Medicare Part D ‘Modernization’ Policies Still Priority Reforms – OMB’s Grogan

Office of Management and Budget health programs official highlights the Administration’s plan for updating and lowering costs in Medicare Part D, including point-of-sale rebates.

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS124273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel